Assessing the incidence of acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy compared to that of vancomycin and cefepime

Sydney Jean Rechtenbaugh 1, Fekadu Fullas 1, *, Kimberly Ann Zellmer 1, Joseph Michael Buren 2, Corey James Thieman 1, and Michael Theodore Padomek 1

1 UnityPoint Health-St. Luke’s, Pharmacy Department, 2720 Stone Park, Boulevard, Sioux City, IA 51104, USA.
2 Sanford USD Medical Center, Pharmacy Department,1305 W18th St., Sioux Falls, SD 57117-5039; USA.
 
Research Article
International Journal of Science and Research Archive, 2021, 02(01), 143-148.
Article DOI: 10.30574/ijsra.2021.2.1.0040
Publication history: 
Received on 03 February 2021; revised on 09 March 2021; accepted on 11 March 2021
 
Abstract: 
Previous studies have shown a correlation between acute kidney injury (AKI) and combination antimicrobial therapy comprising piperacillin-tazobactam and vancomycin. In this study, AKIs were compared in patients who received vancomycin plus piperacillin-tazobactam with those who received vancomycin plus cefepime. We found a statistically significant increase in AKI risk in the vancomycin plus piperacillin-tazobactam group when compared to the vancomycin plus cefepime group using both AKI criteria [KDIGO 18.9% vs. 4.5% (p = 0.0012); RIFLE 11.2% vs. 1.8% (p = 0.0029)]. Vancomycin in combination with piperacillin-tazobactam led to an increased risk of AKI in comparison to vancomycin and cefepime.
 
Keywords: 
Vancomycin Plus Piperacillin-Tazobactam; Vancomycin Plus Cefepime; AKI; KDIGO; RIFLE; Nephrotoxicity; Antibiotics, Antimicrobials
 
Full text article in PDF: 
 
Copyright information: 

Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0